Navigation Links
China-Biotics, Inc. to Hold 2009 Annual Meeting of Stockholders on March 5, 2010
Date:12/10/2009

SHANGHAI, Dec. 10 /PRNewswire-Asia-FirstCall/ -- China-Biotics, Inc. (Nasdaq: CHBT) ("China-Biotics", "the Company"), a leading Chinese firm specializing in the manufacture, research, development, marketing and distribution of probiotics products, today announced that the Company's 2009 Annual Meeting of Stockholders will be held on Friday, March 5, 2010 at the Company's executive offices in Shanghai, China. The Company's board of directors has established Friday, January 8, 2010 as the record date for determining stockholders entitled to vote at the meeting. Management expect that the definitive proxy statement for the meeting will be mailed to stockholders on or about Friday, January 15, 2010.

    The time and venue of China-Biotics' Annual Meeting is as follows:
     Date:   Friday, March 5, 2010
     Time:   10:30 a.m. (Shanghai Time)
     Venue:  5th Floor, Block 15-1, No. 999 Ningqiao Road, Jinqiao Export
             Processing Zone, Pudong, Shanghai, 201206, The People's Republic
             of China.

Stockholder proposals must be received by the Corporate Secretary no later than December 31, 2009 in order to be considered for inclusion in the Company's proxy statement relating to the meeting or to be presented at the meeting. Any such proposal should be mailed to: Corporate Secretary, China-Biotics, Inc., 5th Floor, Block 15-1, No. 999 Ningqiao Road, Jinqiao Export Processing Zone, Pudong, Shanghai, 201206, The People's Republic of China.

China-Biotics' executives will provide an investor presentation to discuss the Company's growth strategy, business outlook, and financial performance. The Company's management and Board members will also accept questions from analysts and investors.

About China-Biotics, Inc.

China-Biotics, Inc., a leading manufacturer of biotechnology products and supplements, engages in the research, development, marketing and distribution of probiotics dietary supplements. Through its wholly owned subsidiary, Shanghai Shining Biotechnology Co., Ltd., the Company has operations in Shanghai. Its proprietary product portfolio contains live microbial nutritional supplements under the "Shining" brand. Currently, the products are sold OTC through large distributors to pharmacies and supermarkets in Shanghai, Jiangsu, and Zhejiang. Currently, China-Biotics is strategically expanding its production capacity of probiotics to meet growing demand in the bulk additive market. For more information, please visit http://www.chn-biotics.com .

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Such factors include, but are not limited to, the Company's ability to market existing and new products, and changes from anticipated levels of sales, future national or regional economic and competitive conditions, market acceptance of its retail store concept, changes in relationships with customers, dependence on its flagship product profits and other factors detailed from time to time in the Company's filings with the United States Securities and Exchange Commission and other regulatory authorities. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

    For more information, please contact:

    China-Biotics, Inc.
     Eva Yan, CFO
     Email: evayan@chn-biotics.com
     Web:   http://www.chn-biotics.com

    CCG Investor Relations
     Crocker Coulson, President
     Phone: +1-646-213-1915 (New York)
     Email: crocker.coulson@ccgir.com
     Web:   http://www.ccgirasia.com

SOURCE China-Biotics, Inc.


'/>"/>
SOURCE China-Biotics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. China-Biotics, Inc. Begins Trial Production at New Facility, Affirms 2010 Revenue Guidance
2. China-Biotics, Inc. Prices $69 Million Public Offering of Common Stock
3. Helix BioPharma Reports On 2009 Annual General Meeting
4. ULURU Inc. Invited to Present Altrazeal(TM) Research at 10th Annual Wound Healing Science and Industry Conference
5. $232 Billion Personalized Medicine Market to Grow 11 Percent Annually, says PricewaterhouseCoopers
6. Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting
7. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
8. TaiGen Biotechnology Reports Phase I and Preclinical Data for TG-0054 at the 2009 American Society of Hematology (ASH) Annual Meeting
9. Tuesday, Dec. 1: News From the 95th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA) in Chicago
10. Covance to Present at Piper Jaffray 21st Annual Health Care Conference
11. Russias Hepatitis C Virus Drug Market Will Grow Nine Percent Annually, Reaching $327 Million by 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ., ... developing innovative inhaled drugs, announced today that it was ... Investments reconstituted its comprehensive set of U.S. and ... "This is an important milestone for Pulmatrix," said Chief ... shareholder awareness of our progress in developing drugs for ...
(Date:6/23/2016)... 2016 Any dentist who has made an implant ... process. Many of them do not even offer this as ... high laboratory costs involved. And those who ARE able to ... a high cost that the majority of today,s patients would ... Parsa Zadeh , founder of Dental Evolutions Inc. and inventor ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer care, ... remain in the eye of the beholder, according to experts who offered insights and ... Journal of Managed Care. For the full issue, click here . , For ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many ... been diagnosed with endometriosis. These women need a treatment plan to not only ... approach that can help for preservation of fertility and ultimately achieving a pregnancy. ...
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding ... of its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. ... James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... A ... procedures that most people are unfamiliar with. The article goes on to state that ... but also many of these less common operations such as calf and cheek reduction. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg ... Legal Elite. The attorneys chosen by their peers for this recognition are considered among ... Greenberg Traurig Shareholders received special honors as members of this year’s Legal Elite Hall ...
Breaking Medicine News(10 mins):